Vor Total Assets vs Accounts Payable Analysis

VOR Stock

USD 1.01 0.03 2.88%

Vor Biopharma financial indicator trend analysis is much more than just breaking down Vor Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vor Biopharma is a good investment. Please check the relationship between Vor Biopharma Total Assets and its Accounts Payable accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

Total Assets vs Accounts Payable

Total Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vor Biopharma Total Assets account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.

The correlation between Vor Biopharma's Total Assets and Accounts Payable is 0.75. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Vor Biopharma, assuming nothing else is changed. The correlation between historical values of Vor Biopharma's Total Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Vor Biopharma are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Assets i.e., Vor Biopharma's Total Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.75

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Assets

Total assets refers to the total amount of Vor Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vor Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Accounts Payable

An accounting item on the balance sheet that represents Vor Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Vor Biopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Vor Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vor Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.As of 12/11/2024, Selling General Administrative is likely to drop to about 18.1 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 103.9 M

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.4M	2.5M	3.2M	3.4M
Total Operating Expenses	69.0M	93.4M	126.0M	63.3M

Reconciled Depreciation Total Operating Expenses

Vor Biopharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt
Total Assets		0.89	0.81	0.76	1.0	0.88	0.93	0.8	-0.58	-0.82	0.75	0.85	0.93	1.0	0.78	0.93	0.97	0.91	0.92	0.94	0.92	-0.37	1.0	-0.01	0.99	0.45
Short Long Term Debt Total	0.89		0.83	0.68	0.87	0.82	0.96	0.9	-0.28	-0.88	0.75	0.62	0.96	0.85	0.93	0.96	0.86	0.87	0.92	0.76	0.96	-0.5	0.85	0.15	0.85	0.41
Other Current Liab	0.81	0.83		0.84	0.78	0.71	0.88	0.83	-0.43	-0.83	0.82	0.72	0.9	0.77	0.88	0.91	0.8	0.77	0.92	0.6	0.87	-0.5	0.77	0.39	0.76	0.32
Total Current Liabilities	0.76	0.68	0.84		0.72	0.75	0.85	0.48	-0.18	-0.79	0.49	0.51	0.85	0.72	0.6	0.85	0.77	0.77	0.9	0.68	0.86	-0.46	0.72	-0.01	0.7	0.73
Total Stockholder Equity	1.0	0.87	0.78	0.72		0.88	0.9	0.79	-0.61	-0.8	0.75	0.87	0.91	1.0	0.76	0.91	0.97	0.9	0.89	0.95	0.9	-0.35	1.0	-0.03	1.0	0.42
Net Tangible Assets	0.88	0.82	0.71	0.75	0.88		0.84	0.66	-0.3	-0.94	0.5	0.67	0.84	0.87	0.75	0.83	0.93	0.99	0.83	0.89	0.85	-0.7	0.87	-0.3	0.87	0.65
Property Plant And Equipment Net	0.93	0.96	0.88	0.85	0.9	0.84		0.8	-0.3	-0.89	0.73	0.65	1.0	0.89	0.85	1.0	0.9	0.89	0.99	0.82	1.0	-0.45	0.89	0.1	0.88	0.55
Current Deferred Revenue	0.8	0.9	0.83	0.48	0.79	0.66	0.8		-0.52	-0.73	0.85	0.73	0.83	0.77	0.96	0.83	0.77	0.72	0.77	0.61	0.8	-0.38	0.77	0.39	0.77	0.04
Net Debt	-0.58	-0.28	-0.43	-0.18	-0.61	-0.3	-0.3	-0.52		0.15	-0.6	-0.89	-0.33	-0.63	-0.36	-0.34	-0.55	-0.31	-0.32	-0.52	-0.28	-0.17	-0.63	-0.22	-0.64	0.27
Retained Earnings	-0.82	-0.88	-0.83	-0.79	-0.8	-0.94	-0.89	-0.73	0.15		-0.58	-0.57	-0.89	-0.78	-0.85	-0.88	-0.85	-0.96	-0.88	-0.74	-0.9	0.8	-0.78	0.07	-0.77	-0.61
Accounts Payable	0.75	0.75	0.82	0.49	0.75	0.5	0.73	0.85	-0.6	-0.58		0.81	0.76	0.74	0.75	0.78	0.63	0.59	0.74	0.5	0.71	-0.27	0.74	0.62	0.74	-0.13
Cash	0.85	0.62	0.72	0.51	0.87	0.67	0.65	0.73	-0.89	-0.57	0.81		0.68	0.88	0.64	0.69	0.81	0.69	0.67	0.75	0.64	-0.24	0.88	0.19	0.88	0.03
Non Current Assets Total	0.93	0.96	0.9	0.85	0.91	0.84	1.0	0.83	-0.33	-0.89	0.76	0.68		0.9	0.87	1.0	0.91	0.9	0.99	0.81	1.0	-0.46	0.9	0.12	0.89	0.53
Cash And Short Term Investments	1.0	0.85	0.77	0.72	1.0	0.87	0.89	0.77	-0.63	-0.78	0.74	0.88	0.9		0.75	0.9	0.97	0.9	0.88	0.95	0.89	-0.34	1.0	-0.04	1.0	0.42
Common Stock Shares Outstanding	0.78	0.93	0.88	0.6	0.76	0.75	0.85	0.96	-0.36	-0.85	0.75	0.64	0.87	0.75		0.86	0.8	0.8	0.83	0.62	0.85	-0.55	0.75	0.27	0.74	0.24
Non Current Liabilities Total	0.93	0.96	0.91	0.85	0.91	0.83	1.0	0.83	-0.34	-0.88	0.78	0.69	1.0	0.9	0.86		0.89	0.88	0.99	0.8	0.99	-0.45	0.89	0.17	0.89	0.5
Other Current Assets	0.97	0.86	0.8	0.77	0.97	0.93	0.9	0.77	-0.55	-0.85	0.63	0.81	0.91	0.97	0.8	0.89		0.93	0.89	0.95	0.9	-0.43	0.97	-0.14	0.97	0.54
Other Stockholder Equity	0.91	0.87	0.77	0.77	0.9	0.99	0.89	0.72	-0.31	-0.96	0.59	0.69	0.9	0.9	0.8	0.88	0.93		0.88	0.88	0.9	-0.7	0.89	-0.19	0.89	0.62
Total Liab	0.92	0.92	0.92	0.9	0.89	0.83	0.99	0.77	-0.32	-0.88	0.74	0.67	0.99	0.88	0.83	0.99	0.89	0.88		0.79	0.99	-0.46	0.88	0.13	0.87	0.56
Net Invested Capital	0.94	0.76	0.6	0.68	0.95	0.89	0.82	0.61	-0.52	-0.74	0.5	0.75	0.81	0.95	0.62	0.8	0.95	0.88	0.79		0.82	-0.31	0.95	-0.34	0.95	0.59
Property Plant And Equipment Gross	0.92	0.96	0.87	0.86	0.9	0.85	1.0	0.8	-0.28	-0.9	0.71	0.64	1.0	0.89	0.85	0.99	0.9	0.9	0.99	0.82		-0.47	0.89	0.07	0.88	0.58
Short Long Term Debt	-0.37	-0.5	-0.5	-0.46	-0.35	-0.7	-0.45	-0.38	-0.17	0.8	-0.27	-0.24	-0.46	-0.34	-0.55	-0.45	-0.43	-0.7	-0.46	-0.31	-0.47		-0.34	0.12	-0.33	-0.42
Total Current Assets	1.0	0.85	0.77	0.72	1.0	0.87	0.89	0.77	-0.63	-0.78	0.74	0.88	0.9	1.0	0.75	0.89	0.97	0.89	0.88	0.95	0.89	-0.34		-0.04	1.0	0.42
Capital Stock	-0.01	0.15	0.39	-0.01	-0.03	-0.3	0.1	0.39	-0.22	0.07	0.62	0.19	0.12	-0.04	0.27	0.17	-0.14	-0.19	0.13	-0.34	0.07	0.12	-0.04		-0.04	-0.62
Net Working Capital	0.99	0.85	0.76	0.7	1.0	0.87	0.88	0.77	-0.64	-0.77	0.74	0.88	0.89	1.0	0.74	0.89	0.97	0.89	0.87	0.95	0.88	-0.33	1.0	-0.04		0.4
Short Term Debt	0.45	0.41	0.32	0.73	0.42	0.65	0.55	0.04	0.27	-0.61	-0.13	0.03	0.53	0.42	0.24	0.5	0.54	0.62	0.56	0.59	0.58	-0.42	0.42	-0.62	0.4

Click cells to compare fundamentals

Vor Biopharma Account Relationship Matchups

Vor Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.8M	75.9M	242.6M	299.4M	198.1M	151.6M
Other Current Liab	1.5M	6.1M	4.9M	4.8M	7.1M	4.8M
Total Current Liabilities	2.2M	10.2M	10.2M	13.1M	15.6M	10.8M
Total Stockholder Equity	7.6M	48.3M	216.3M	250.6M	150.7M	122.2M
Net Tangible Assets	(17.4M)	(59.1M)	216.3M	250.6M	288.2M	302.6M
Property Plant And Equipment Net	728K	21.8M	22.5M	57.1M	50.1M	27.9M
Net Debt	(6.5M)	(30.2M)	(101.8M)	(18.8M)	4.3M	4.5M
Retained Earnings	(17.9M)	(61.2M)	(130.1M)	(222.2M)	(340.1M)	(323.1M)
Accounts Payable	693K	2.4M	1.5M	1.8M	815K	1.3M
Cash	6.5M	48.5M	119.8M	57.7M	31.4M	48.5M
Non Current Assets Total	2.3M	26.8M	28.2M	62.4M	57.3M	32.5M
Cash And Short Term Investments	6.5M	48.5M	207.5M	230.2M	137.2M	115.7M
Common Stock Shares Outstanding	37.1M	37.1M	37.2M	39.6M	67.2M	41.0M
Liabilities And Stockholders Equity	9.8M	75.9M	242.6M	299.4M	198.1M	151.6M
Non Current Liabilities Total	693K	17.4M	16.2M	35.6M	31.8M	18.7M
Other Current Assets	205K	567K	6.9M	6.7M	6.8M	3.9M
Other Stockholder Equity	458K	2.2M	346.4M	473.6M	490.9M	515.4M
Total Liab	2.2M	27.6M	26.3M	48.8M	47.4M	29.3M
Net Invested Capital	(17.4M)	(59.1M)	216.3M	250.6M	150.7M	98.8M
Property Plant And Equipment Gross	728K	21.8M	24.6M	61.7M	58.2M	30.6M
Total Current Assets	7.5M	49.1M	214.4M	237.0M	140.8M	119.1M
Capital Stock	25.1M	107.3M	4K	7K	6.3K	6.0K
Net Working Capital	5.4M	38.9M	204.2M	223.8M	125.2M	108.3M
Property Plant Equipment	728K	21.8M	6.9M	12.6M	14.5M	9.3M

Pair Trading with Vor Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Vor Stock

0.69	FLGC	Flora Growth Corp	Pair Corr
0.66	GNFT	Genfit	Pair Corr
0.6	IMAB	I Mab	Pair Corr

The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.

The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC